BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 24,369 Shares of Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 24,369 shares of the stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $302.87, for a total value of $7,380,639.03. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

John Oyler also recently made the following trade(s):

• On Monday, December 15th, John Oyler sold 75,631 shares of BeOne Medicines stock. The stock was sold at an average price of $307.79, for a total transaction of $23,278,465.49.

BeOne Medicines Stock Up 0.6%

Shares of NASDAQ ONC opened at $306.05 on Thursday. The company’s 50 day moving average price is $328.72 and its 200-day moving average price is $306.91. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.17 and a current ratio of 2.39. BeOne Medicines Ltd. – Sponsored ADR has a 52-week low of $170.99 and a 52-week high of $385.22. The company has a market capitalization of $36.28 billion, a P/E ratio of 600.10 and a beta of 0.45.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of BeOne Medicines in a research report on Wednesday. Zacks Research lowered BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a report on Wednesday, October 8th. Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Friday, October 3rd. Finally, Morgan Stanley raised their price objective on shares of BeOne Medicines from $350.00 to $383.00 and gave the stock an “overweight” rating in a research report on Monday, October 20th. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, BeOne Medicines has a consensus rating of “Moderate Buy” and a consensus target price of $365.79.

Hedge Funds Weigh In On BeOne Medicines

Large investors have recently modified their holdings of the company. Parallel Advisors LLC bought a new stake in BeOne Medicines during the 2nd quarter valued at $59,000. Aaron Wealth Advisors LLC acquired a new position in shares of BeOne Medicines during the second quarter valued at about $200,000. Farther Finance Advisors LLC bought a new stake in shares of BeOne Medicines during the second quarter worth about $39,000. Avanza Fonder AB acquired a new stake in shares of BeOne Medicines in the 2nd quarter worth about $199,000. Finally, Public Employees Retirement System of Ohio bought a new position in BeOne Medicines in the 2nd quarter valued at about $3,491,000. 48.55% of the stock is currently owned by institutional investors.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.